Last reviewed · How we verify

Indigo (INDIGO)

Provepharm Sas · FDA-approved active Small molecule

Unfortunately, the mechanism of action of Indigo is unknown.

Indigo is a small molecule drug developed by Hahnemann Laboratories, INC. and currently owned by Provepharm Sas. Unfortunately, there is limited information available on its target, drug class, and approved indications. As a result, its mechanism of action, safety considerations, and commercial status are unclear. Further research is needed to determine its potential therapeutic applications and risks.

At a glance

Generic nameINDIGO
SponsorProvepharm Sas
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Mechanism of action

This means that we don't know how it works at a basic level to help the body. In general, medications work by interacting with specific molecules or systems in the body to produce a desired effect. Without this information, it's difficult to understand how Indigo might help patients.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity